755 100% Svr4 and Favorable Safety of Abt-493 + Abt-530 Administered for 12 Weeks in Non-Cirrhotic Patients With Genotypes 4, 5, or 6 Infection (Surveyor-I)

Authors :: Federico J. Mensa
Edward Gane
Jacob Lalezari
Ran Liu
Tarek Hassanein
Chih-Wei Lin
Teresa Ng
Armen Asatryan
Susan Greenbloom
Jens Kort
Source :: Gastroenterology. 150:S1047
Publication Year :: 2016
Publisher :: Elsevier BV, 2016.

Subjects :: 0301 basic medicine
03 medical and health sciences
medicine.medical_specialty
Hepatology
business.industry
Internal medicine
030106 microbiology
Genotype
Gastroenterology
medicine
business

Tools